A mid‑pandemic night's dream: Melatonin, from harbinger of anti‑inflammation to mitochondrial savior in acute and long COVID‑19 (Review)
International Journal of Molecular Medicine,
Год журнала:
2024,
Номер
53(3)
Опубликована: Янв. 26, 2024
Coronavirus
disease
2019
(COVID‑19),
a
systemic
illness
caused
by
severe
acute
respiratory
distress
syndrome
2
(SARS‑CoV‑2),
has
triggered
worldwide
pandemic
with
symptoms
ranging
from
asymptomatic
to
chronic,
affecting
practically
every
organ.
Melatonin,
an
ancient
antioxidant
found
in
all
living
organisms,
been
suggested
as
safe
and
effective
therapeutic
option
for
the
treatment
of
SARS‑CoV‑2
infection
due
its
good
safety
characteristics
broad‑spectrum
antiviral
medication
properties.
Melatonin
is
essential
various
metabolic
pathways
governs
physiological
processes,
such
sleep‑wake
cycle
circadian
rhythms.
It
exhibits
oncostatic,
anti‑inflammatory,
anti‑aging
properties,
exhibiting
promise
use
numerous
disorders,
including
COVID‑19.
The
preventive
effects
melatonin
have
widely
explored
number
conditions
well‑established
experimental
ischemia/reperfusion
investigations,
particularly
coronary
heart
stroke.
Clinical
research
evaluating
COVID‑19
shown
improved
outcomes,
reduced
hospitalization
durations;
however,
trials
are
small.
can
alleviate
mitochondrial
dysfunction
COVID‑19,
improve
immune
cell
function
provide
However,
potential
remains
underexplored
funding
limitations
thus
further
investigations
required.
Язык: Английский
Effectiveness of SARS-CoV-2 testing strategies
Cochrane library,
Год журнала:
2025,
Номер
2025(2)
Опубликована: Фев. 24, 2025
Язык: Английский
Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(7), С. 1837 - 1837
Опубликована: Март 22, 2024
Background:
Despite
advancements
in
vaccination,
early
treatments,
and
understanding
of
SARS-CoV-2,
its
impact
remains
significant
worldwide.
Many
patients
require
intensive
care
due
to
severe
COVID-19.
Remdesivir,
a
key
treatment
option
among
viral
RNA
polymerase
inhibitors,
lacks
comprehensive
studies
on
factors
associated
with
effectiveness.
Methods:
We
conducted
retrospective
study
2022,
analyzing
data
from
252
hospitalized
COVID-19
treated
remdesivir.
Six
machine
learning
algorithms
were
compared
predict
influencing
remdesivir’s
clinical
benefits
regarding
mortality
hospital
stay.
Results:
The
extreme
gradient
boost
(XGB)
method
showed
the
highest
accuracy
for
both
(95.45%)
stay
(94.24%).
Factors
worse
outcomes
terms
included
limitations
life
support,
ventilatory
support
needs,
lymphopenia,
low
albumin
hemoglobin
levels,
flu
and/or
coinfection,
cough.
For
stay,
vaccine
doses,
lung
density,
pulmonary
radiological
status,
comorbidities,
oxygen
therapy,
troponin,
lactate
dehydrogenase
asthenia.
Conclusions:
These
findings
underscore
XGB’s
effectiveness
accurately
categorizing
undergoing
remdesivir
treatment.
Язык: Английский
Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study
Therapeutic Advances in Infectious Disease,
Год журнала:
2024,
Номер
11
Опубликована: Янв. 1, 2024
Background:
Even
though
worldwide
death
rates
from
coronavirus
disease
2019
(COVID-19)
have
decreased,
the
threat
of
progression
and
for
high-risk
groups
continues.
Few
direct
comparisons
between
available
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
antivirals
been
made.
Objective:
We
aimed
to
compare
two
SARS-CoV-2
(nirmatrelvir/ritonavir
remdesivir)
against
all-cause
hospitalization
or
death.
Design:
This
is
a
propensity
score-matched
cohort
study.
Methods:
included
all
outpatients
with
COVID-19
in
tertiary
referral
center
Mexico
City
1
January
2022
31
July
2023.
The
primary
outcome
was
28
days
after
symptom
onset.
secondary
COVID-19-associated
Logistic
regression
analysis
characteristics
associated
multi-group
comparison
Kaplan–Meier
survival
estimates
were
performed.
Results:
Of
1566
patients
analyzed,
783
did
not
receive
antiviral
treatment,
451
received
remdesivir,
332
nirmatrelvir/ritonavir.
median
age
60
years
(interquartile
range:
46–72),
62.5%
female
97.8%
had
at
least
one
comorbidity.
use
nirmatrelvir/ritonavir
an
absolute
risk
reduction
8.8%
relative
90%
remdesivir
6.4%
66%
In
multivariable
analysis,
both
reduced
odds
28-day
[nirmatrelvir/ritonavir
ratio
(OR)
0.08
–
95%
confidence
interval
(CI):
0.03–0.19,
OR
0.29
CI:
0.18–0.45].
Conclusion:
outpatients,
early
treatment
lower
Язык: Английский
Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach
Antonio Ramón,
Andrés Bas Castillo,
Santiago Herrero González
и другие.
Опубликована: Фев. 24, 2024
Despite
widespread
vaccination,
early
treatments,
and
improved
understanding
of
the
disease,
effects
SARS-CoV-2
infection
remain
significant
worldwide.
Many
patients
still
suffer
from
severe
COVID-19,
necessitating
admission
to
intensive
care
units.
Remdesivir
is
a
primary
treatment
option
among
viral
RNA
polymerase
inhibitors
for
hospitalized
patients.
However,
there
lack
studies
examining
factors
influencing
its
effectiveness
in
this
context.
We
conducted
retrospective
study
throughout
2022,
analyzing
clinical,
laboratory,
sociodemographic
data
252
COVID-19
treated
with
remdesivir.
Six
machine
learning
algorithms
were
compared
validated
predict
associated
loss
clinical
benefit
remdesivir
terms
mortality
hospital
stay.
Data
extracted
electronic
health
records.
The
eXtreme
Gradient
Boost
(XGB)
method
achieved
highest
balanced
accuracy
both
(95.45%)
stay
(94.24%).
Factors
worse
outcomes
use
included
limitation
life
support
treatment,
need
ventilatory
(especially
invasive
mechanical
ventilation)
on
day
14
after
first
dose
remdesivir,
lymphopenia,
low
levels
albumin
hemoglobin,
presence
flu
and/or
coinfection,
cough.
number
doses
vaccine,
patchy
lung
density,
bilateral
pulmonary
radiological
status,
comorbidities,
oxygen
therapy,
troponin
lactate
dehydrogenase
levels,
asthenia.
These
findings
highlight
XGB
as
strong
candidate
accurately
categorizing
undergoing
treatment.
Язык: Английский
The parallel lives of pandemics: COVID‑19 and obesity
Experimental and Therapeutic Medicine,
Год журнала:
2024,
Номер
27(5)
Опубликована: Март 6, 2024
The
present
article
discusses
the
interconnectedness
of
coronavirus
disease
2019
(COVID‑19)
and
obesity
as
global
health
crises.
similarities
between
two
conditions
are
highlighted;
these
include
shared
risk
factors
comorbidities,
impact
on
immune
system.
also
mentions
challenges
faced
in
combating
both
pandemics,
including
misinformation
prejudice
against
obesity.
It
development
therapeutic
medications
vaccines
for
COVID‑19
potential
injectable
incretin
analogues
weight
loss.
Socioeconomic
issues
addressed,
with
being
more
prevalent
lower
socioeconomic
groups
cost
treatments
a
barrier
those
need.
emphasizes
need
comprehensive
sustainable
solutions,
public
interventions,
education,
policy
changes
equitable
distribution
resources,
to
address
Язык: Английский
The treatment of COVID-19: lessons learned and future directions
Future Virology,
Год журнала:
2024,
Номер
19(8-9), С. 315 - 323
Опубликована: Июнь 12, 2024
In
response
to
the
COVID-19
pandemic,
this
manuscript
examines
current
standard-of-care
treatments
in
an
inpatient
and
outpatient
setting,
as
well
novel
treatment
regimens
that
should
be
explored.
On
29
February
2024,
NIH
updated
Treatment
Guidelines
page
for
last
time.
Over
2
years,
options
have
remained
relatively
static.
Though
there
are
ongoing
studies
evaluating
therapeutics,
most
notably
Accelerating
Therapeutic
Interventions
Vaccines
6
(ACTIV-6)
Strategies
Treatments
Respiratory
Infections
Viral
Emergencies
(STRIVE)
studies,
they
will
both
likely
end
enrollment
2024.
This
leave
many
promising
without
a
platform
tested.
It
is
imperative
we
continue
find
ways
rigorously
test
like
simnotrelvir,
VV116,
ensitrelvir
vilobelimab,
metformin
combination
of
spironolactone
sitagliptin
create
better
avenues
patients
worldwide.
Язык: Английский